Health and Healthcare
BioHealth Business Daily (BMRN, DVAX, SEPR, STEM, PCYC, OCLS)
Published:
Last Updated:
Today is an unusually active day for many emerging biotech stocks in the news and we are seeing significant moves in response. We have more detail on each with appropriate links through to more analysis and data at BioHealthInvestor.com or VSInvestor.com:
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is seeing exponential trading volume in stock and options after a 10% rise today.
Dynavax Technologies Corporation (NASDAQ: DVAX) is up over 50%after the FDA removed a clinical hold on its hepatitis treatment.
The fight over the Sepracor, Inc. (NASDAQ: SEPR) acquisition has now gone to the level of a class action status. We noted the very low P/E and multiple valuations yesterday on this one.
StemCells, Inc. (NASDAQ: STEM) traded slightly higher on word that it will soon begin a study with the University of California, San Francisco Children’s Hospital using purified human neural stem cells as a possible treatment for Pelizaeus-Merzbacher Disease.
Pharmacyclics Inc. (NASDAQ: PCYC) was trading up on news that its right offering is oversubscribed.
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) is trading higher on report that it has been assigned a Medicare HCPCS code for its recently introduced Microcyn Skin & Wound HydroGel.
JON C. OGG
SEPTEMBER 10, 2009
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
